Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00673049 · ClinicalTrials.gov registry record · Phase 3
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00673049 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 583 participants.
The verdict
NCT00673049, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
Interventions
- DRUG Erlotinib
- DRUG CP 751,871 (Figitumumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00673049
The ClinicalTrials.gov registry entry for NCT00673049 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 583 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00673049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00673049 about?
NCT00673049 is a clinical study titled "Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer". The objective of this study is to test a clinical benefit of the addition of CP 751,871 to erlotinib therapy in patients with advanced NSCLC of non adenocarcinoma histology. The primary endpoint is Overall Survival (OS).
What is the current status of trial NCT00673049?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2008-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00673049?
The interventions under investigation include: Erlotinib (DRUG), CP 751,871 (Figitumumab) (DRUG).
Who is sponsoring clinical trial NCT00673049?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.